Virtual Library

Start Your Search

Myung-Ju Ahn



Author of

  • +

    MA03 - Clinomics and Genomics (ID 119)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • +

      MA03.08 - Discussant - MA03.05. MA03.06, MA03.07 (Now Available) (ID 3724)

      10:30 - 12:00  |  Presenting Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA08 - Pawing the Way to Improve Outcomes in Stage III NSCLC (ID 127)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Treatment of Locoregional Disease - NSCLC
    • Presentations: 1
    • Now Available
    • +

      MA08.03 - Adjuvant Pembrolizumab in N2 Positive NSCLC Treated with Concurrent Chemoradiotherapy Followed by Surgery: Phase II, Prospective Study (Now Available) (ID 1744)

      15:15 - 16:45  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Background

      The standard treatment option for stage IIIA-N2 subgroup is still under discussion with controversies. We hypothesize that immune checkpoint inhibitor consolidation therapy could have an additional role in prolongation of the disease-free survival (DFS) for stage IIIA-N2 NSCLC treated with tri-modalities therapy.

      Method

      This is a phase 2 study evaluating the clinical efficacy of pembrolizumab treatment after CCRT with curative resection in stage IIIA-N2 NSCLC pts (NCT03053856). Pathologically confirmed pts were treated with five cycles of CCRT, weekly paclitaxel (50mg/m2) and cisplatin (25mg/m2) combined with radiotherapy (total of 44Gy over 22 fractions) followed by curative resection. Adjuvant Pembrolizumab (200mg fixed dose) is applied every three weeks up to 2 years or until disease recurrence. The primary objective is disease-free survival of more than 20 months. The first patient was recruited in October 2017, and the data for this abstract was locked at 20th of January, 2019.

      Result

      Total of 40 pts were screened, and 37 pts received treatment. Median age was 64 years (range 39-74), and twenty-three pts were male (62.2%). As a curative surgery, pts received lobectomy (n=34), bi-lobectomy (n=2), or pneumonectomy (n=1). Adenocarcinoma was predominant (n=27, 73.0%). After the neoadjuvant CCRT, down-staging were observed in nine pts (24.3%). The median follow-up duration was 10.6 months (range 3.1-17.2), and pts received a median of 11 cycles (range 1-22) of adjuvant pembrolizumab. DFS is not reached. Fourteen patients discontinued treatment due to disease progression (n=9), adverse events (n=4) and withdraw consent (n=1). There was a case of grade 4 pneumonitis and a case of grade 3 autoimmune hepatitis which lead to discontinuation of the treatment. Otherwise, grade 1-2 hypothyroidism (n=6), pneumonitis (n=5), skin rash (n=3) were observed. Patients with severe immune-related adverse event showed a significantly high percentage of Ki-67 + cells among CD8 T-cells in peripheral blood.

      Conclusion

      This study is the first study to demonstrate the feasibility of adjuvant pembrolizumab monotherapy in stage IIIA-N2 patients. Updated clinical outcome will be presented at the conference.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA19 - Looking at PROs in Greater Detail - What Patients Actually Want and Expect (ID 147)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • +

      MA19.06 - Successful Development of Realtime Automatically Updated Data Warehouse in Health Care (ROOT-S) (Now Available) (ID 584)

      11:30 - 13:00  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Background

      Clinical information is often not recorded in an organized way, and converting it to a structured format can be a time-consuming task that may not successfully capture all facets of the information. Clinical Data Warehouse is a real time database that consolidates data from a variety of clinical sources to present a unified view. However, the clinical data extracted from the CDW have not only structured data (SD) but also natural language (NP) generated during clinical practice, and there is a limitation that it is difficult to apply to clinical trials because it is not structured and formatted to find key-point contents. This study aims at developing a systematic and comprehensive cohort through an automatic real-time update system called CDW.

      Method

      The aim of this study was to evaluate clinical data of non-small cell lung cancer, small cell lung cancer, head and neck cancer, thymic cancer, and mesothelioma. In this study, we developed a unique algorithm that is optimized for each disease category using comprehensive natural language processing (NLP) systems and structured information from unstructured free text and structured data capture (SDC). We developed an algorithm using clinical information of patients diagnosed and treated during the past 10 years and designated validation sets of patients diagnosed and treated in 2018 for validation that these algorithms work automatically.

      Result

      We collected clinical data of 23,735 NSCLC patients, 2,077 SCLC patients, 5,032 head and neck cancer patients, 3,948 esophageal cancer patients, 747 thymic cancer patients and 138 mesothelioma patients diagnosed at Samsung Medical Center. We could demonstrate using the validation set that the program accurately extracts the data needed for the cohort of each cancer. The program is updated automatically every 24 hours, the source of each data is indicated separately, and the data that need to be integrated is transformed and systematically organized. The biggest advantage is that the scattered information is systematically integrated and automatically buildup to match the patient's cohort, so you can capture most updated survival or test results or treatment outcomes almost in real time. Data on the development of this program will be presented.

      Conclusion

      This study is the first study that successfully developed and validated real-time updated cohort using CDW. This study suggests a blueprint for constructing a big data -based cohort for clinical research and is expected to be a landmark trial. The detailed analysis of each cancer through the development of the program will be presented.

      wclc.png

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA20 - Thymic Tumors: From Molecular to Clinical Results and New Challenges in Other Rare Thoracic Tumors (ID 149)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Thymoma/Other Thoracic Malignancies
    • Presentations: 1
    • Now Available
    • +

      MA20.05 - Follow-Up Update of 2 Phase II Studies of Pembrolizumab in Thymic Carcinoma (Now Available) (ID 1120)

      11:30 - 13:00  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Background

      Two phase II studies of pembrolizumab 200 mg every 3 weeks in advanced thymic carcinoma have recently been published (Giaccone et al. Lancet Oncol. 2018, study #1; Cho et al. JCO 2018, study #2). Both studies reported a response rate in about 20% of patients and a rate of autoimmune disorders that is higher than in other tumor types.

      Method

      This report provides a follow-up update of these 2 studies, with particular emphasis on duration of response, and occurrence of autoimmune disorders. Both studies included patients with thymic carcinoma who had progressed after at least one line of chemotherapy.

      Result

      In study #1 a total of 40 patients with advanced thymic carcinoma were treated, with a median follow up of 40.6 months. The response rate did not change (22.5%) compared to the original publication, however one patient who had developed myositis, myocarditis and myasthenia gravis (MG), continues to be in nearly complete response after only two cycles of pembrolizumab, 36 months from initiation of treatment. One patient who had developed myositis and hepatitis with unclear signs of MG developed overt MG symptoms several months after the interruption of therapy. No other new autoimmune disorders were observed (6/40 = 15%). Five patients completed 2 years of treatment according to protocol and 4 of them elected to continue treatment. Three patients who had been off therapy were rechallenged with pembrolizumab upon progression (one responded). Median duration of response was 38 months (from 22.4 in initial report), median PFS was 4.2 months (identical) and median survival was 25.8 months (24.9 in the initial report).

      At completion of this study, an amendment was introduced to add epacadostat 10 mg BID to pembrolizumab in the same patient population. Four patients were treated before the study was closed after the results of a randomized trial of the combination in melanoma failed to meet its primary endpoint. No patient responded (2 stable and 2 progressions). One patient developed grade 2 myocarditis.

      In study #2 a total of 26 patients with advanced thymic carcinoma were included, with a median follow up of 33.4 months. The response rate (19.2%) did not change, and no other autoimmune disorder appeared since the initial publication (5/26 = 19%). Median duration of response (9.7 months), median PFS (6.1 months) and median survival (14.5 months) did not change compared to the initial publication. No additional autoimmune disorders were documented compared to the original publication. A total of 5 patients received 2 years of pembrolizumab according to protocol; no patient continued beyond 2 years or was retreated upon progression with pembrolizumab.

      Conclusion

      These two studies confirm definite activity of pembrolizumab in advanced thymic carcinoma. Recently pembrolizumab was included in the NCCN guidelines for thymic carcinoma. No additional autoimmune disorders were noted after discontinuation of pembrolizumab. There are significant differences in duration of response and overall survival in the 2 studies and potential factors are being investigated. In study #1 pembrolizumab was continued beyond 2 years in several patients and rechallenge was an available option.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA21 - Non EGFR/MET Targeted Therapies (ID 153)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Targeted Therapy
    • Presentations: 1
    • Now Available
    • +

      MA21.10 - Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI (Now Available) (ID 1705)

      14:30 - 16:00  |  Presenting Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Background

      EGFR tyrosine kinase inhibitor (TKI) has successfully improved clinical outcome in non-small cell lung cancer (NSCLC) with activating EGFR mutation. However, up to 40% of TKI treated patients present with disease progression in the central nerve system (CNS) either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib is a 3rd generation EGFR TKI effective in T790M mutant NSCLC and characterized by high blood-brain barrier penetration. In this phase II, multicenter prospective single-arm two cohort study, the clinical efficacy of 160mg of osimertinib in T790M mutant BM or LM patients progressed on prior EGFR TKI was evaluated. (NCT0325712)

      Method

      BM only patients were included in the BM cohort (n=40). Patients with cerebrospinal cytology confirmed LM with or without BM were included in the LM cohort (n=40). 3rd generation TKI, including 80mg of osimertinib, was exposed to 18 patients in BM and 16 patients in LM cohort. T790M need to be identified from either tissue, plasma or cerebrospinal fluid. The primary endpoint was overall response rate (ORR) (H1=30%) for BM cohort and overall survival (OS) (H1=5months) for LM cohort, respectively.

      Result

      Median follow-up duration was 7.9 months for BM and 8.3 months for LM cohort. In BM cohort, median progression-free survival (PFS) was 7.3 months (95% confidential interval [CI] 3.6-13.7), and median OS was not reached (NR). Intracranial ORR and disease control rate (DCR) was 40.0% and 77.5%. Extracranial ORR and DCR was 30.0% and 67.5%. In LM cohort, median PFS was 8.9 months (95%CI 5.6-NR) and median OS was 13.2 months (95%CI 8.0-NR). When response of leptomeningeal lesion is separately evaluated, CR rate was 25.0% (n=10) and non-CR/non-PR rate was 65.0% (n=26). Extracranial ORR and DCR was 22.5% and 85.0%. Intracranial median PFS was not reached in both BM and LM cohort. Grade 3 adverse event (AE) was observed in 7 BM and 11 LM patients. Four patients required dose reduction due to AE. Among the patients who previously received 3rd generation TKI, 33.3% (6 out of 18) in BM cohort and 81.2% (13 out of 16) in LM cohort showed an intracranial DCR to 160mg of osimertinib. Extended survival analyses and exploratory outcomes will be presented at the conference.

      Conclusion

      In this study, 160mg of osimertinib demonstrated promising ORR and survival benefit with tolerable safety profile in EGFR T790M positive NSCLC patients with CNS metastasis who progressed on prior EGFR TKI.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    OA04 - Immuno Combinations and the Role of TMB (ID 126)

    • Event: WCLC 2019
    • Type: Oral Session
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • +

      OA04.07 - Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial (Now Available) (ID 901)

      15:15 - 16:45  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Background

      In the Phase 3 MYSTIC study (NCT02453282), blood tumour mutational burden, at various thresholds from ≥12 to ≥20 mut/Mb (bTMB≥20), has been associated with improved OS and PFS with first-line durvalumab (D; anti-PD-L1) +/- tremelimumab (T; anti-CTLA-4) versus platinum-based chemotherapy (CT). Specific gene mutations have been associated with resistance (STK11 and KEAP1) or sensitisation (ARID1A) to anti-PD-(L)1 monotherapy. However, the relationship between gene alterations and response to anti-PD-(L)1 ± anti-CTLA-4 are not well characterised. Here we explore associations between mutations and survival outcomes in the MYSTIC patient population.

      Method

      Circulating tumour DNA from baseline blood specimens was profiled using the GuardantOMNI platform. Samples were available from 1003 patients (89.7% of ITT; 943 mutation-evaluable). Survival outcomes were analysed in patients with (m) or without (wt) non-synonymous somatic mutations in STK11, KEAP1, or ARID1A.

      Result

      In the mutation-evaluable population, STK11m, KEAP1m, and ARID1Am frequencies were 16%, 18% and 12%, respectively (19%, 20%, and 11% [nonsquamous]; 7%, 13%, and 15% [squamous]). Across treatment arms, patients with STK11m or KEAP1m had a shorter median OS (mOS) than patients with STK11wt (D, 10.3 vs 13.3 mo; D+T, 4.4 vs 11.3 mo; CT, 6.7 vs 13.1 mo) or KEAP1wt (D, 7.6 vs 14.6 mo; D+T, 9.2 vs 11.3 mo; CT, 6.3 vs 13.3 mo) mNSCLC. In the D+T arm, patients with ARID1Am had a longer mOS than patients with ARID1Awt mNSCLC (D, 8.6 vs 13.7 mo; D+T, 23.2 vs 9.8 mo; CT, 10.6 vs 12.4 mo). Additional mutational analyses will be presented.

      Conclusion

      In these analyses from the MYSTIC study, poorer outcomes were observed across treatment arms in patients with mNSCLC and mutations in STK11 or KEAP1 compared with those without the corresponding mutations. In patients receiving D+T, ARID1Am was associated with survival benefits compared with ARID1wt. These data are exploratory and require further validation.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    OA14 - Update of Phase 3 Trials and the Role of HPD (ID 148)

    • Event: WCLC 2019
    • Type: Oral Session
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • +

      OA14.07 - Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced NSCLC Treated with Immunotherapy (Now Available) (ID 1067)

      11:30 - 13:00  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Background

      Hyperprogressive disease (HPD), characterized by accelerated tumor progression, has been proposed as a new pattern of progression following immune checkpoint inhibitor (ICI) treatment. The aim of this study was to describe the characteristics of HPD and investigate its predictive markers.

      Method

      Clinical and radiological findings of 335 advanced non-small cell lung cancer (NSCLC) patients treated with ICI monotherapy were retrospectively analyzed. Radiological data were quantitatively and longitudinally analyzed for tumor size and volume by comparing baseline and follow-up computerized tomography results. The findings were matched to individual genomic profiles generated by deep sequencing of 380 genes.

      Result

      Among 135 patients with progressive disease (PD), as assessed by RECIST, 48 (14·3% of total and 35·6% among PD) and 44 (13·1% of total and 32·6% among PD) were found to have HPD by volumetric (HPDV) and one-dimensional (HPDR) analysis, respectively. HPDV patients were associated with significantly inferior overall survival (OS) compared with non-HPDV PD patients (median OS (months), 4·7 [95% confidence interval (CI), 3·5–11·9)] vs. 7·9 [95% CI, 6·0–13·5], p=0·004); OS did not differ between HPDR and non-HPDR patients. HPDV status was an independent OS factor. Derived neutrophil-to-lymphocyte ratio (dNLR) greater than 4 and lactate dehydrogenase (LDH) greater than the upper normal limit were significantly associated with HPDV. Moreover, we identified coinciding KRAS and STK11 mutations in the HPDV cohort (3/16), while none were found in the non-HPDV cohort (0/28).

      Conclusion

      Defining HPD treated with ICI based on volumetric measurement is more precise than that based on one-dimensional analysis. Pre-ICI dNLR, LDH, and concurrence of STK11 and KRAS mutations could, thus, be used as potential biomarkers for HPD prediction.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.01 - Advanced NSCLC (ID 158)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 4
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.01-133 - Randomized Open-Label Study of Bintrafusp Alfa (M7824) vs Pembrolizumab in Patients with PD-L1 Expressing Advanced 1L NSCLC (Now Available) (ID 741)

      09:45 - 18:00  |  Presenting Author(s): Myung-Ju Ahn

      • Abstract
      • Slides

      Background

      Transforming growth factor β (TGF- β) promotes tumor progression via immune- and non–immune-related processes. Bintrafusp alfa* (M7824) is an innovative first-in-class bifunctional fusion protein composed of 2 extracellular domains of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 monoclonal antibody against PD-L1. Targeting these independent and complementary pathways may restore and enhance antitumor responses. An expansion cohort of the NCT02517398 study of patients with advanced NSCLC (n=80) treated with bintrafusp alfa in the second-line setting presented at ESMO 2018 showed an objective response rate of 86% in the subgroup with high PD-L1 tumor expression at the recommended phase 2 dose (1200 mg intravenously [IV] every 2 weeks [Q2W]). Observed data support the hypothesis that bintrafusp alfa may be superior to other PD-(L)1 inhibitors, including pembrolizumab, for the treatment of NSCLC. Based on the promising antitumor activity and manageable safety profile, this study will evaluate bintrafusp alfa treatment in patients with advanced NSCLC in the 1L setting.

      Method

      Here we present a global, randomized trial comparing bintrafusp alfa vs pembrolizumab in the 1L treatment of patients with metastatic NSCLC with high PD-L1 expression levels. Patients in this study must have a histologically confirmed diagnosis of advanced NSCLC with high PD-L1 expression on tumor cells (defined as either ≥80% by the Dako 73-10 pharmDx kit or ≥50% by the Dako 22C3 pharmDx kit since both assays are expected to select a similar patient population at their respective cut-offs). ECOG performance status must be 0 or 1. Patients must not have received prior systemic treatment for advanced NSCLC. Patients with tumors with actionable mutations (for which targeted therapy is locally approved) are not eligible. Patients will receive 1200 mg Q2W or pembrolizumab 200 mg Q3W as an IV infusion until confirmed disease progression, unacceptable toxicity, or trial withdrawal. Dual primary endpoints are progression-free survival and best overall response; key secondary endpoints include overall survival, duration of response, and safety. Estimated enrollment is 300 patients. Clinical trial information: NCT03631706. *Proposed INN.

      © 2019 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting. All rights reserved.

      Result

      Section not applicable

      Conclusion

      Section not applicable

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P1.01-134 - SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib (ID 2209)

      09:45 - 18:00  |  Presenting Author(s): Myung-Ju Ahn

      • Abstract
      • Slides

      Background

      The toxicity profile of the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) osimertinib makes it an attractive backbone for combination with other targeted agents, possibly overcoming acquired resistance mechanisms. Combination with a MET-inhibitor is an intuitive approach as MET-amplification was identified as the most common mechanism of resistance to osimertinib in preliminary ctDNA data from the Phase III FLAURA (15% of patients) and AURA3 (19% of patients) studies. Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, potent and highly selective MET-TKI that had an acceptable safety profile when combined with osimertinib in the Phase Ib TATTON study, providing the basis for this Phase II SAVANNAH study (NCT03778229). Other mechanisms of acquired resistance to osimertinib, including secondary EGFR mutations (e.g. C797S), RAS/RAF activation, and oncogenic gene fusions, provide additional opportunities for developing osimertinib-based combinations.

      Method

      Eligible patients will have histologically or cytologically confirmed EGFR-mutant, locally advanced or metastatic non-small cell lung cancer (NSCLC), and MET-driven (MET+) disease by central fluorescence in situ hybridization (FISH), central immunohistochemistry (IHC), or local next-generation sequencing (NGS; retrospectively confirmed by central FISH/IHC). Patients must have documented radiological progression following 1–3 lines of prior therapy (must include osimertinib). Patients will receive osimertinib plus savolitinib in 28-day cycles. The primary objective is efficacy (RECIST 1.1) by overall response rate (ORR) in patients who are MET+ by central FISH. Secondary endpoints include: ORR (MET+ by central IHC and all patients); progression-free survival, overall survival, duration of response, percent change in tumor size, HRQoL, and EGFR mutation ctDNA clearance (MET+ by central FISH, central IHC, and all patients); safety, and pharmacokinetics (all patients). Based on the TATTON study, we anticipate enrolling ~172 patients with MET+ disease, to include ≥117 patients with MET+ disease by central FISH. Enrolment began in Q1 2019. Ongoing development of complementary trials targeting other osimertinib resistance mechanisms will also be discussed.

      Result

      Section not applicable

      Conclusion

      Section not applicable

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P1.01-136 - Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: A Systematic Literature Review of Prevalence and Clinical Outcomes (ID 2175)

      09:45 - 18:00  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Slides

      Background

      Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer sensitivity to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). About 90% of detected mutations are either deletions in exon 19 or the exon 21 L858R substitution. Comparatively few data are available on the prevalence, treatment sensitivity or clinical outcomes associated with the remaining 10%, termed ‘uncommon mutations’. To collate available published evidence, we conducted a systematic literature review (SLR) focussing on these uncommon EGFR mutations in metastatic and locally advanced NSCLC.

      Method

      Embase, MEDLINE and the Cochrane Library were searched using terms for NSCLC and EGFR; abstracts from relevant congresses were also reviewed. Screening identified clinical trials and observational studies published 2012–2019 that included patients with uncommon EGFR mutations (all mutations except exon 19 deletions, L858R and T790M). For prevalence data, only studies in which exons 18–21 were sequenced in their entirety were considered relevant; studies that used targeted methods to detect EGFR mutations were not included. We assessed the overall prevalence of uncommon EGFR mutations, and also compared response to treatment and progression-free survival (PFS) in patients with common and uncommon mutations.

      Result

      In total, 20 epidemiology and 90 clinical studies met the inclusion criteria, with broad variation in geography and study population. The prevalence of uncommon mutations varied widely across studies, between 1.0% and 18.2% of all EGFR mutations (Figure). The most frequently reported uncommon mutations, either singly or occurring in double/triple mutations, were G719X (0.9–4.8% of all EGFR mutations), exon 20 insertions (0.8–4.2%), L861X (0.5–3.5%) and S768I (0.5–2.5%). Patients with common mutations typically experienced better treatment response and longer PFS than patients with uncommon mutations when receiving TKIs. However, there was considerable heterogeneity across studies, which is likely to result partly from variations in TKI-sensitivity between different types of EGFR mutations and disparities in the uncommon mutation types represented in each study. In several studies, exon 20 insertions were associated with worse outcomes than other uncommon mutations, particularly mutations in exon 18.

      john et al_figure 1.jpg

      Conclusion

      This comprehensive SLR indicates that uncommon mutations may comprise a clinically significant proportion of the EGFR mutations occurring in NSCLC worldwide. As there are apparent disparities in TKI-sensitivity between some of the most frequently reported uncommon mutations, assessment and reporting of outcomes by specific mutation type will prove invaluable in identifying the most appropriate treatment strategy in each case.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P1.01-97 - Modified RANO-LM Criteria to Evaluate the Radiological Response of Osimertinib in EGFR T790M Positive NSCLC with Leptomeningeal Metastases (ID 1719)

      09:45 - 18:00  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      There is no standardized method in tracking the clinical response of leptomeningeal (LM) disease. Based on the recently proposed RANO criteria for LM, we made a further modification which could apply to the clinical trials and real clinical setting. In this study, the feasibility of modified RANO-LM criteria is tested in the exploratory dataset from our prospective clinical trials conducted in EGFR T790M positive non-small cell lung cancer patients with LM (NCT0325712).

      Method

      Based on the previous RANO-LM criteria, up to five leptomeningeal nodules, leptomeningeal enhancement and cranial nerve (CN) enhancement from the baseline was recorded and then changes were scored between -3 to 3 at each post-baseline time point of brain MRI imaging using modified RANO-LM criteria. According to the pre-defined scoring system (figure), all LM lesions were categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Presence of hydrocephalus or parenchymal lesion is seperately assessed as non-LM lesion

      abstract_figure.png

      Result

      Response of osimertinib in LM was evaluated in 34 patients. Baseline MRI identified LM enhancement in 67.6% (n=23), CN enhancement in 55.9% (n=19), hydrocephalus in 35.3% (n=12) and parenchymal metastases in 79.4% (n=27) but no nodular lesion (n=0). LM specific overall response rate was 63.9% by showing CR (n=10, 29.4%), PR (n=13, 38.3%), SD (n=8, 23.5%), PD (n=1, 2.9%) in evaluable patients. Eight patients showed treatment resistance by showing disease aggravation in LM lesion (n=2), non-LM lesion (n=5) and both (n=1).

      Conclusion

      Modified RANO-LM criteria seems to be effective in evaluating treatment response and disease progression in patients with LM. Despite the complexity of the scoring system, modified RANO-LM criteria is a feasible method to evaluate LM status which could be applicable both to the clinical trials and to daily clinical practice. Further validation in independent patient cohort will be performed.

  • +

    P1.04 - Immuno-oncology (ID 164)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 2
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.04-06 - Tumor Microenvironment Landscape in Lung Adenocarcinoma by Single-Cell Sequencing (ID 1227)

      09:45 - 18:00  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      Lung cancer is the leading cause of cancer cell death in worldwide. Failure of early detection, high recurrence rate and metastasis all contribute to the low survival rate in this detrimental disease. In particular, frequent brain metastasis confers an imperative challenge in the management of lung cancer. Single-cell RNA sequencing provides specific profiling of cell populations at the single-cell level. Interpretation of single-cell transcriptome data for the discovery of therapeutic targets and prognostic biomarkers is an ongoing challenge in precision cancer medicine. Especially, the influence of immune microenvironment in tumor has been accepted as a key factor for determining the therapeutic outcome. Despite the diversity of immune infiltrates in lung adenocarcinoma, single-cell RNA sequencing has not yet been applied for a large-scale tumor and immune profiling.

      Method

      Samples were obtained from the primary tumor, lymph node or brain metastases, and pleural fluids of 44 patients with lung adenocarcinoma. Following lung tumor resection, normal lung tissues from a distal region as well as normal lymph nodes were collected for comparison. We dissociated the whole tissues into single cell suspension and then performed scRNA-seq using droplet-based 10x Genomics Chromiunm platform.

      Result

      After quality filtering, we cataloged a total of 208,506 cells into 9 distinct cell lineages annotated by expression of known marker genes. We identified epithelial cells including cancer cells, stromal cells (fibroblasts and endothelial cells), immune cells (T, NK, B, myeloid, and MAST cells) as common cell types, and oligodendrocytes uniquely from brain metastases. The most abundant immune cell populations at the lung tumor site were T lymphocytes and myeloid cells. Notably, primary tumor and lymph node metastases showed substantial differences in the immune cell composition. These differences reflected the original tissue microenvironment, grossly altered by tumor progression and invasion. Therefore, our lung adenocarcinoma atlas illustrates the dynamic cellular landscape during cancer progression which may reveal progression associated changes for each cellular component in unprecedented scale and manner.

      Conclusion

      These results provide specific tumor microenvironmental patterns in lung adenocarcinoma. Thus, single cell-level transcriptome profiles provide clues to expand therapeutic windows into the combination therapy with immune and anti-cancer reagents.

    • +

      P1.04-24 - Circulating Suppressive Immune Cells Predict the Efficacy of Anti PD-1 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer (ID 466)

      09:45 - 18:00  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      The major suppressive immune cells in tumor sites are myeloid derived suppressor cell (MDSC), tumor associated macrophage (TAM), and regulatory T (Treg) cell, and the major roles of these suppressive immune cells include hindering T cell activities and supporting tumor progression and survival. In this study, we analyzed the pattern of various circulating suppressive immune cells in patients with non-small cell lung cancer (NSCLC) to see whether those suppressive immune cells hinder T cell activities leading to poor clinical outcomes.

      Method

      Baseline blood samples were collected from stage I to IV NSCLC patients (n=59), and baseline and one week after the therapy paired blood samples from stage IIIB to IV NSCLC patients (n=83) undergoing anti PD-1 immunotherapy either pembrolizumab or nivolumab. The efficacies of peripheral blood suppressive immune cells along with CD39+CD8+ T cells individually or collectively in anti-PD-1 immunotherapy were evaluated using flow cytometry and T cell suppressive assay.

      Result

      G-MDSCs, M-MDSCs, TAMs, Treg cells, and CD39+CD8+ T cells increased according to NSCLC stage, and MDSCs effectively suppressed T cell activities and induced T cell exhaustion ex vivo. Further, the analysis of 83 NSCLC patients treated with anti-PD-1 immunotherapy demonstrated that low G-MDSCs (PPFS = 0.03, Pos = 0.04), M-MDSCs (PPFS = 0.04, Pos = 0.005), TAMs (PPFS = 0.007, Pos = 0.01), and CD39+CD8+ T cells (PPFS = 0.57, Pos = 0.02) were associated with longer progression-free survival (PFS) and overall survival (OS) compared with high groups. When we performed combined analysis of three suppressive immune cells, G-MDSCs, M-MDSCs, and TAMs collectively, patients who had low frequency of all three suppressive immune cells showed more prominent difference of PFS (6.7 months vs 2 months; P = 0.006), OS (8.5 months vs 4.2 months; P = 0.004), and response rate (94.5% vs 50%) compared to patients with high levels of all three suppressive immune cells. We further sorted patients with all suppressive immune cells plus CD39+CD8+ T cells low and high. Again, PFS (6.1 months vs 0.8 months; P = 0.006), OS (11 months vs 2.4 months; P = 0.01), and response rate (85.7% vs 16.7%) of all suppressive immune cells low and CD39+ CD8+ T cells low group were significantly increased.

      Conclusion

      The analysis of 83 advanced NSCLC patients treated with anti-PD-1 immunotherapy demonstrated that G-MDSC, M-MDSC, TAM and CD39+CD8+ T cell frequencies in peripheral blood individually and collectively might be useful as potential predictive biomarkers.

  • +

    P1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 186)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.16-46 - Genetic Testing Patterns, Treatment Characteristics, and Overall Survival in ALK-Positive Metastatic NSCLC Patients Treated with Ceritinib (ID 1345)

      09:45 - 18:00  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Slides

      Background

      In patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC), the majority of data on ALK inhibitor (ALKi) use and related survival outcomes are from clinical trials; information from community practice is sparse. This study therefore sought to assess ALK testing patterns, treatment characteristics, and overall survival (OS) in patients with mNSCLC treated with ceritinib in routine practice.

      Method

      In this retrospective cohort study, medical records for patients with ALK-positive mNSCLC (diagnosed during 2008-2016; aged ≥18 years) were selected from sites in Canada and Europe. Patients were treated with ceritinib in any line for mNSCLC and had at least 8 months of follow-up after ceritinib initiation, except for patients who died sooner than 8 months. Baseline patient characteristics, treatment patterns, and timing of ALK testing relative to start of therapy lines were descriptively assessed. OS was assessed using Kaplan-Meier methods.

      Result

      87 patients were selected (median age: 53 years). Nearly 56% of patients had been tested for ALK mutation before initiating the first-line therapy (1L); 72% were tested before 2L and 77% before 3L. The most common regimens were cisplatin/pemetrexed (25%) in 1L, crizotinib (28%) in 2L, and ceritinib (35%) in 3L. Over two-thirds (68%) received treatment with at least 2 ALKis. The most commonly observed ALKi sequences were crizotinib followed by ceritinib (52%), ceritinib only (23%), and crizotinib followed by ceritinib followed by alectinib (12%). Median OS (95% CI) from mNSCLC diagnosis was 39 (33.1-50.1) months. Median OS (95% CI) from treatment initiation was 36 (28.2-48.9) months for 1L, 29 (22.1-42.8) months for 2L, and 23 (14.0-40.5) months for 3L.

      Conclusion

      Only slightly more than half of patients with ALK-positive mNSCLC were tested for ALK mutation before initiating the first-line therapy during the study period. ALKis were the preferred therapies in the second and third lines. Median OS following the first-line therapy initiation was nearly 3 years among the selected study patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-18 - ORION: A Phase 2, Randomised, Multicentre, Double-Blind Study to Assess Efficacy and Safety of Durvalumab+Olaparib Versus Durvalumab Alone as Maintenance Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) (Now Available) (ID 636)

      10:15 - 18:15  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Slides

      Background

      Systemic chemotherapy for first-line (1L) metastatic NSCLC shows mixed outcomes. Results from studies using immunotherapy alone or combined with chemotherapy as 1L treatment in patients (pts) with metastatic NSCLC represent a substantial advance, but further improvement is needed. Increased deoxyribonucleic acid damage triggered by polyadenosine 5’diphosphoribose polymerase inhibition may confer antitumour activity, modify tumour immunogenicity and further sensitise tumours to immune checkpoint inhibition, thus promoting a more durable antitumour response. This Phase 2, randomised, multicentre, double-blind study (NCT03775486) is designed to assess the efficacy and safety of durvalumab+olaparib versus durvalumab alone as maintenance therapy in pts whose stage IV NSCLC has not progressed following 1L platinum-based chemotherapy+durvalumab.

      Method

      Adult pts with stage IV NSCLC with tumours lacking activating EGFR mutations and ALK fusions are eligible. In the initial therapy phase, all pts will receive durvalumab (1500 mg intravenously [IV]) concurrent with platinum-based doublet therapy. Durvalumab+chemotherapy will be administered for 4 cycles for both squamous NSCLC (nanoparticle albumin-bound [nab]-paclitaxel+carboplatin or gemcitabine+carboplatin/cisplatin) and nonsquamous NSCLC (nab-paclitaxel+carboplatin or pemetrexed+carboplatin/cisplatin). Pts whose disease does not progress (complete or partial response [CR/PR] or stable disease [SD]; investigator-assessed RECIST 1.1) will be randomised (1:1) to durvalumab (1500 mg IV, every 4 weeks) + either olaparib (300 mg, oral, twice daily) or its matching placebo until disease progression. Randomisation will be stratified based on objective response to durvalumab+chemotherapy (CR/PR or SD) during the initial therapy phase and histology (squamous or nonsquamous).

      Result

      The primary endpoint is progression-free survival (PFS) (investigator-assessed, RECIST 1.1). Secondary endpoints are overall survival, PFS in pts with homologous recombination repair-related gene mutation, objective response rate, duration of response, health-related quality of life, pharmacokinetics and immunogenicity of durvalumab, as well as safety.

      Conclusion

      The study start date was 21 December 2018 and patient enrolment is ongoing. All patients will be followed for survival until the end of the study. The estimated primary completion date is 5 October 2020 and the estimated study completion date is 2 June 2022.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.09 - Pathology (ID 174)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Pathology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.09-07 - Multiple Immunohistochemistry of Non-Small Cell Lung Cancers Reveals Distinct Immune Context (ID 1232)

      10:15 - 18:15  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      Immune checkpoint blockade improves survival in a subset of patients with non-small cell lung cancer (NSCLC). Though increased tumor infiltrating lymphocytes (TILs) correlate with better outcome in many human cancers, biomarkers that predict response to PD-1 pathway inhibitors remain largely unknown. Therefore, a comprehensive evaluation of the composition and distribution of TILs is necessary to demonstrate their roles.

      Method

      To determine the predictive significance of specific immune cells in the tumor microenvironment, we used multiples IHC. Multiplex IHC is a powerful investigative tool which provides objective quantitative data describing the tumor immune context in both immune subset number and location. To evaluate the immune context broadly we used the OPAL staining panel contains CD8, CD4, CD20, CD68, FOXP3, and panCK.

      Result

      Pathologic tumor specimens from 101 patients with recurred or metastatic NSCLC were analyzed. Tumors exhibited a high degree of heterogeneity in the immune infiltrate and there was no significant difference when immune infiltrates were compared by tumor histology. Furthermore, there were no significant immune cell differences in EGFR mutant tumors or tumors that did not harbor mutations in adenocarcinoma. We observed increased Tregs (CD4+/FOXP3+) in PD-L1-positive tumors as compared with PD-L1-negative tumors. Our results showed that the infiltration levels of most T-cell subpopulations within tumor did not significantly associated with survival. However, high infiltration of B cells significantly correlated with overall survival.

      Conclusion

      Increased infiltration of B cells into tumor regions is an independent predictor of better overall survival in NSCLC. These findings suggest that tumor-infiltrating B cells could act as a clinical factor in anti-PD-1 immunotherapy for NSCLC.

  • +

    P2.12 - Small Cell Lung Cancer/NET (ID 180)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.12-14 - A Pilot Study of Serial Plasma Metabolomics in Small Cell Lung Cancer Patients (ID 1623)

      10:15 - 18:15  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      Small cell lung cancer (SCLC) is among the deadliest cancers. SCLC is characterized by high proliferation and high turn-over metabolism. There are few results of metabolomics analysis correlated with outcomes of SCLC patients.

      Method

      This study included 27 patients after excluding eight who were treated with immunotherapy or placebo. Median age of the patients was 65 years (range, 43 to 82), and 23 male patients were included. Three (11%) never-smoker patients were included. Twelve patients were limited disease (LD) and 15 were extensive disease (ED) including three patients with brain metastases. All patients were treated with etoposide and platinum (EP, 20 cisplatin and 7 carboplatin), and nine among 12 patients with LD were treated concurrently with radiotherapy since 3rd cycle of EP chemotherapy. We planned to collect blood samples at diagnosis (T1), after two cycles of chemotherapy (T2) and at the first progression (T3). We analyzed 27 T1 samples, 14 T2 samples, and 18 T3 samples. Metabolomics analysis included 183 metabolites (21 amino acids, 19 biogenic amines, 40 acylcarnitines, 14 lysoglycerophosphocholines, 74 glycerophospholipids, and 14 sphingolipids, 1 hexose) using AbsoluteIDQ® p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria).

      Result

      Baseline levels of five acylcarnitines and one glycerophospholipid were associated with progression free survival whereas, the amino acid proline and acylcarnitine (C10:1) were associated to overall survival. In comparison to LD, amino acid, asparagine was elevated while two acylcarnitines (C10:2 and C12:1) were lower in patients with ED. After two cycles of chemotherapy without progression, plasma concentration of 37 lipids (5 LysoPC, 24 glycerophospholipids, 3 sphingolipids and 5 acylcarnitines) were increased. Five mono and poly unsaturated glycerophosphospholipids (PC aa and PC ae) with C42 and C44 fatty acid chains were significantly (adj p < 0.05) lower. Of these, chemotherapy and induction of remission induced change in glycerophospholipid PC ae C42:5 was related to overall survival (p < 0.05). The 7 glycerophospholipids with C42 and C44 fatty acids were elevated when patients relapsed post chemotherapy. Five glycerophospholipid metabolites were significantly lower in response to chemotherapeutic exposure. The metabolites tended to increase towards baseline levels upon relapse.

      Conclusion

      With this preliminary exploratory study, we identified association of metabolites and initial status and outcomes of SCLC. We observed significant modulation in glycerophospholipids upon chemotherapy and relapse which may serve as indicators of therapeutic response and resistance. Further exploration and validation is being underway in larger SCLC population.

  • +

    P2.14 - Targeted Therapy (ID 183)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 3
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.14-54 - High Incidence of CNS Metastases in Advanced or Recurrent Non-Small Cell Lung Cancer Patients with RET Fusion (ID 1758)

      10:15 - 18:15  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      Chromosomal rearrangements involving RET, with incidence of 1-2% in non-small-cell lung cancer, define a distinctive molecular subset. Here, we aim to determine the clinicopathological characteristics of patients with advanced NSCLC harboring the RET fusion gene.

      Method

      We identified 59 consecutive cases with RET rearrangements by using break-apart fluorescence in situ hybridization (n=14), next-generation sequencing (n=37), or both (n=8). Clinical data, including baseline characteristics, initial presentation, responses to chemotherapy and/or immunotherapy were retrospectively analyzed.

      Result

      The median age was 56 years, and 53% of patients were male. Approximately half of the patients (51%) were never-smokers. Adenocarcinoma was the predominant histologic subtype (90%), followed by pleomorphic (3%), neuroendocrine (3%), squamous cell (2%), and small cell carcinoma (2%). For the 19 patients with small primary lesions (<3cm), 32% (6/19) had N2 and 37% (7/19) had N3 disease. 17 patients (29%) had an intracranial lesion at the initial presentation or at the time of recurrence, and additional 11 patients (19%) developed brain metastasis during follow-up. Cerebrospinal fluid cytology exam confirmed leptomeningeal seeding in four patients (7%) with concomitant parenchymal metastasis. The median time to development of brain metastases was 19.0 months (range 3.8-51.8).

      Of 30 patients whose fusion partners were identified, kinesin family member 5B (KIF5B) was the most common, followed by coiled-coil domain containing 6 gene (CCDC6), nuclear receptor coactivator 4 (NCOA4), and myosin 5C (MYO5C) and lisH domain and HEAT repeat-containing protein KIAA1468 homolog (KIAA1468). Additionally, a novel fusion partner, phytanoyl-CoA 2-hydroxylase interacting protein like (PHYHIPL), was reported in one patient. Only two patients harbored concomitant EGFR mutation, and no ALK alterations were reported.

      The median overall survival was 35.3 months (95% confidence interval [CI]: 21.7-48.9). In 46 patients who were treated with pemetrexed-based chemotherapy, the overall response rate (ORR) and progression-free survival (PFS) time were 53.0% and 8.5 months (95% CI: 6.3-10.7), respectively. In 13 patients who were treated with immunotherapy, the ORR and PFS were 7.7% and 1.5 months (95% CI: 1.3-1.7), respectively, with no significant difference according to the level of PD-L1 expression.

      Conclusion

      Our study revealed the unique clinical characteristics and outcomes of advanced NSCLC patients harboring RET fusion gene. Considering the high incidence of CNS metastases, relatively poor response to immunotherapy, and a recent development of RET kinase inhibitors (such as cabozantinib and vandetanib), more efforts are warranted for identification of patients with RET fusion as a candidate for targeted therapies.

    • +

      P2.14-57 - Efficacy of 3rd Generation EGFR-TKIs After Failing First or Second Generation EGFR-TKIs in EGFR Mutation-Positive NSCLC (ROOT-EGFR) (ID 1474)

      10:15 - 18:15  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      Over the past decade, treatment of EGFR mutation –positive NSCLC has been revolutionized with the development of next generation EGFR TKIs. Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available in Korea. Recent trials have compared the available and emerging EGFR TKIs head to head. The highly anticipated findings of the phase III FLAURA trial showed a nearly doubling of PFS with frontline osimertinib, a third-generation TKI, versus erlotinib or gefitinib.The optimal sequence of EGFR TKIs is still controversial. And many countries 3rd generation EGFR TKI is not readily available. The purpose of this study is to analyze the efficacy in patients who received first-line gefitinib, erlotinib, or afatinib and followed by 3rd generation EGFR-TKIs.

      Method

      This non-interventional observational study through big data analysis will retrospectively collect de-identified patient data from clinical data warehouse (CDW) using a unique algorithm with Standard Query Language (SQL) called ROOT project.

      Result

      Over 10 years, 2,358 patients were diagnosed recurrent or metastatic non-small cell lung cancer and received 1st or 2nd generation EGFR TKIs at Samsung Medical Center. 72.9% (1720/2358) of EGFR mutation-positive NSCLC patients received 1st or 2nd generation EGFR-TKIs as first line palliative chemotherapy. In total population, 30.8% (727/2358) patients received 3rd generation EGFR TKIs. Among them, patients who received 3rd generation EGFR TKI after 1st or 2nd generation EGF TKIs showed better overall survival (45.0 months (95% CI, 41.8-48.2). Among 1720 patients who received 1st or 2nd generation EGFR-TKIs as first line palliative chemotherapy, 313 patients received 3rd generation EGFR-TKIs as 2nd line chemotherapy and 200 patients received as more than 3rd line chemotherapy. However, there was no difference of overall survival between them (44.0 months vs 47.0months, p-value=0.104).

      Conclusion

      This study was meaningful as a study of what can be the best sequence in EGFR-TKI treatment. Updated and detail clinical and exploratory biomarker outcome will be presented at the meeting.

    • +

      P2.14-61 - Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer (ID 1219)

      10:15 - 18:15  |  Author(s): Myung-Ju Ahn

      • Abstract

      Background

      ROS1 is a receptor tyrosine kinase (RTK) that is not usually expressed at high levels in normal lung tissue. The wild-type function of ROS1 is unknown, and a natural ligand has not been identified. ROS1 gene rearrangements occur in ~1-2% of patients with NSCLC, and have also been identified in colorectal, gastric and ovarian cancers, glioblastoma and cholangiocarcinoma. ROS1 rearrangements with oncogenic potential have been found to constitutively activate ROS1 signaling, and although it remains unclear exactly how the ROS1 fusion proteins are activated, the PI3K/AKT, MAPK/ERK and JAK/STAT3 pathways are known to be involved. Thus, ROS1-rearranged NSCLCs are ‘addicted’ to ROS1 for cell growth and survival. Knocking down or pharmacologically inhibiting ROS1 has been reported to inhibit growth or induce apoptosis in ROS1-rearranged cell lines. Entrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1 and ALK. The combined results of two clinical trials demonstrated the efficacy of entrectinib in ROS1-rearranged NSCLC. Because the development of drug resistance is inevitable, it would be helpful to determine the mechanisms of entrectinib resistance in a ROS1-rearranged tumor model so that future therapeutic strategies can be developed.

      Method

      To investigate the effects of entrectinib on ROS1-rearranged NSCLC, we used HCC78 cells harboring an SLC34A2-ROS1 fusion. Entrectinib-resistant HCC78 (HCC78ER) cells were newly established in our laboratory through the exposure of HCC78 cells to gradually increasing concentrations of entrectinib (starting at 100 nM and ending with 5 μM) over 6 months.

      Result

      Here, we characterized the molecular basis of resistance in entrectinib-resistant ROS1-rearranged HCC78 cells (HCC78ER cells). These cells were analyzed by next-generation sequencing and genetic profiling, which revealed the acquisition of KRAS G12C and the amplification of KRAS and FGF3. However, there were no secondary mutations in the ROS1 kinase domain. We also found that sustained ERK activation was involved in entrectinib resistance, and that combined treatment with selumetinib resensitized HCC78ER cells to entrectinib in cell viability and colony formation assays.

      Conclusion

      Our data suggest that activation of the RAS signaling pathway can cause entrectinib resistance in ROS1-rearranged NSCLC, and is unlikely to be overcome by sequential single agent ROS1-targeting strategies against such tumors. Instead, co-targeting ROS1 and MEK may be an effective strategy for overcoming entrectinib resistance in ROS1-rearranged NSCLC.

  • +

    P2.18 - Treatment of Locoregional Disease - NSCLC (ID 191)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment of Locoregional Disease - NSCLC
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.18-01 - A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC (Now Available) (ID 2200)

      10:15 - 18:15  |  Author(s): Myung-Ju Ahn

      • Abstract
      • Slides

      Background

      The TGF-β pathway promotes tumor immunosuppression, and its inhibition may enhance the antitumor activity of PD-(L)1 monoclonal antibodies and reduce radiation-induced lung fibrosis. Bintrafusp alfa is an innovative first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1. In a phase 1 study, second-line bintrafusp alfa therapy demonstrated promising antitumor activity in advanced non-small cell lung cancer (NSCLC) (NCT02517398). In preclinical studies, bintrafusp alfa plus radiotherapy showed enhanced antitumor activity compared with radiotherapy alone in mouse models. This study is evaluating the efficacy and safety of bintrafusp alfa with concurrent chemoradiation (cCRT) followed by bintrafusp alfa vs cCRT plus placebo followed by durvalumab in patients with unresectable stage III NSCLC.

      Method

      This global, multicenter, double-blind, randomized, controlled study of bintrafusp alfa (NCT03840902) includes adults with histologically documented stage III locally advanced, unresectable NSCLC, ECOG performance status ≤1, adequate pulmonary function, and life expectancy ≥12 weeks. Patients with tumors with actionable mutations (EGFR, ALK translocation, ROS-1 rearrangement) are also eligible. Mixed small cell lung cancer and NSCLC histology; pleural effusions greater than minimal, exudative, or cytologically positive; significant acute or chronic infections; prior chemotherapy or immune checkpoint inhibitor therapy for NSCLC; and current use of immunosuppressive medication are exclusion criteria. Patients are randomized to receive either bintrafusp alfa 1200 mg IV every 2 weeks (Q2W) with cCRT for 6 weeks followed by bintrafusp alfa 1200 mg IV Q2W (arm A) or placebo with cCRT for 6 weeks followed by durvalumab 10 mg/kg IV Q2W (arm B) until confirmed disease progression, unacceptable toxicity, or treatment ≤1 year. The primary endpoint is progression-free survival; secondary endpoints include overall survival, safety, lung function assessment, objective response, duration of response, pharmacokinetics, and immunogenicity. This phase 2 trial was activated on April 2, 2019 and first patient in is anticipated for May 22, 2019. Target enrollment: 350 patients.

      Result

      Section not applicable

      Conclusion

      Section not applicable

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    PL02 - Presidential Symposium including Top 7 Rated Abstracts (ID 89)

    • Event: WCLC 2019
    • Type: Plenary Session
    • Track:
    • Presentations: 1
    • Now Available
    • +

      PL02.12 - Discussant - PL02.11 (Now Available) (ID 3915)

      08:00 - 10:15  |  Presenting Author(s): Myung-Ju Ahn

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.